Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Olivier D ARROS China

Investment banking boutique specialized in cross-border medical device transactions.
We would like to bring to your next events exclusive opportunities from Western companies in the fields of: robotics, cancer screening, liver disease diagnostic, robotics, cardiovascular and respiratory
Website:
www.mavietech.com
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Headquartner in China
Yes
Medtech Category
MAVIE Technologies
Managing Partner 
Functionality
Management

Youwen Dai United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
BD Director 

Yves Decadt Switzerland

At Biolingus, we believe we can make life better for many people in the world, not just in rich countries, but across the globe.
BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is "inspired by nature" using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery. Our company focusses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.
BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia.
See also video made by the Swiss Chinese Chamber of Commerce : https://www.linkedin.com/posts/yvesdecadt_icbc-vischer-gunvor-activity-6737745258496434176-8BZc
Website:
www.biolingus.ch
Company Size (Fulltime employees)
11-50
Year of foundation
2014
Looking for
Please specify your partnering goal
(1) Outlicensing our lead assets for China - Liraglutide oral (sublingual) - Exenatide oral (sublingual) - insulin + (fixed dose combination of insulin with exenatide ; sublingual) (2) partnering on development of proprietary peptides
Now raising (In USD)
30 MM
Headquartner in China
No
Plan in China
Commercializing all our products
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
Liraglutide SL|sublingual liraglutide|obesitas, diabetes type II|phase 1b/2a|
Assets Information 2
Exenatide SL|sublingual exenatide|obesitas, diabetes type II|preclinical|
Biotech/Pharma Asset Stage
Biolingus
CEO 
Functionality
Management

Mr Denis Demarais Germany

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!
Website:
https://ec.europa.eu/eipp/desktop/en/projects/project-11851.html
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Please specify your partnering goal
Bring together technology & funds for improving “China Focus” healthcare situation on an equal basis.
Funding Status
Seeking investors for Series A
Now raising (In USD)
1,665,454 USD
Headquartner in China
No
Plan in China
Rius Medical unique position as CDMO (contract development and manufacturing organization) is not limited to drug delivery. Yes, drug delivery programs bring EUR 130 million revenue sooner than “Rius Medical’s blood transfusion” program. However, Rius Medical’s path to becoming a market leader in healthcare in promoting excellence, innovation and good business practices, is driven by its “blood transfusion” program. The Plan in China is local Jobs in China for manufacturing of stem cells derived “blood transfusion” products. Also drug delivery via "Third-Generation red blood cells for drug delivery" that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes, is region-specific; as in Europe, USA and China regions due to ABO blood group and other antigens being region-specific!
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
eRBC|Red Blood Cells for Drug Delivery|Oncology|Prototype Assembly|N/A
Biotech/Pharma Asset Stage
Mr Denis Demarais
Rius Medical UG (Haftungsbeschränkt)
LinkedIn logo Founder and CEO 
Functionality
Management

Tunca Demirci Turkey

RA/QA and clinical services consultancy company dedicated to medical devices.
We have been providing services to a wide variety of medical devices in every Class to prepare technical documents for CE certification and FDA authorization.
Services that are sought most are
Compiling or updating Technical Files according to MDR (EU 2017/745) and IVDR (EU 2017/746)
CEP, CER, PMCF Plan, Clinical Trial Protocols
QMS updates
Sterilization Validation, Process Validation, Packaging Validation, Software Validation, etc.
GAP, Mock, Supplier Audits
Medical device registration in 140 countries
Website:
https://www.adviqual.com.tr/en
Company Size (Fulltime employees)
1-10
Year of foundation
2015
Looking for
Please specify your partnering goal
We are ready to share our team of experts resource with any consultancy or CRO companies who would like to add new services or enriches its resources.
Headquartner in China
No
Plan in China
Providing services to all Asia with Chinees partners
Your Service Name
Consultancy for CE certification & FDA authorization
Service Description
Preparing any technical or clinical document that is required for MDR , IVDR or FDA authorization
Target Client Type
Medical device producers
AdviQual End. Dan. San. Tic. Ltd. Şti.
Business Development Director 
Functionality
Business Development

Paul DeRidder United States

Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory
Website:
www.paulderiddermd.com
Company Size (Fulltime employees)
1-10
Year of foundation
2007
Looking for
Funding Status
self
Headquartner in China
No
Plan in China
Bring US based biomedical technology into China markets
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
BioValleyCHINA Ventures
President 
Functionality
Business Development

David Dill United States

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.
Website:
www.wellesleypharma.com
Company Size (Fulltime employees)
1-10
Year of foundation
2010
Looking for
Funding Status
Have raised $4.4 million of the $14.4 million needed to finish the clinical trial work needed for FDA approval.
Headquartner in China
No
Plan in China
To find a licensee that wants to provide a drug needed nightly by ten of millions of people in China alone and investors to fund our Phase 3 trial work.
Wellesley Pharmaceuticals, LLC
CEO & President 
Functionality
Management

DIMITAR DIMITROV Bulgaria

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET

Website:
http://micar21.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Please specify your partnering goal
Drug Discovery
Funding Status
raising
Now raising (In USD)
2500000
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Investment Focus
Oncology project
Slides Deck
(pdf, 939.67KB)
CEO 
Functionality
Management

Martin Duenas United States

OniX invest in companies in two ways: (1) Directly through it OniX Venture Fund and (2) Indirectly through its OniX hub members (includes pharma, VC, PE, family offices and private foundations)
Website:
https://www.onixhub.com/ | https://www.onixempirefund.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Funded
Headquartner in China
No
Plan in China
TBD
OniX Hub
Founder/CEO 
Functionality
Management

Robert Dunne Ireland

Our company develops and manufactures technology and applications for glycoprotein separation and analysis. We are focussed on the biopharmaceutical industry. We also have customers in medical diagnostic and cosmetic companies.
Our facility is based on the campus of Dublin City University in Ireland.
We have developed an extensive network of contacts not only customers but also opinion leaders in glybiology.

Website:
GlycoSeLect Ltd
Company Size (Fulltime employees)
1-10
Year of foundation
2013
Looking for
Please specify your partnering goal
Joint venture to develop downstream processing applications
Funding Status
Series A
Now raising (In USD)
900,000
Headquartner in China
No
Plan in China
Seek local partner to establish glycobiology specialist company supplying better glycoprotein product analysis and manufacturing technology with support for application development.
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
RPL lectins for glycoprotein product analysis & manufacturing applications|Glycan specific proteins for use in detecting and separating glycoproteins|Product analysis and manufacturing, especially vaccines and mAbs.|Worldwide available
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 164.08KB)
GlycoSeLect Ltd
CEO 
Functionality
Management